Sirtex: Don’t wait until it’s too late

Scott Power


Sirtex - SIRFLOX presentation at ASCO and initial positive feedback from physicians has done little to change our view that while SIR-Spheres microspheres works in the liver, as expected from a locoregional therapy, the results will have limited impact on driving adoption in first-line metastatic colorectal cancer (mCRC). With the most amenable patient population to treatment unknown, we would use share strength to exit positions as we do not believe these data will translate into a significant increase in near-term sales. We make no changes to our estimates (SRX, Reduce, Price Target A$13.42). Report attached .

Scott Power
Scott Power
Senior Analyst

Senior Analyst at Morgans covering healthcare, life science, telecommunications, technology and media. I've spent the last twenty years investing in and researching emerging companies and have developed a wide network of contacts across these...


No areas of expertise

I would like to

Only to be used for sending genuine email enquiries to the Contributor. Livewire Markets Pty Ltd reserves its right to take any legal or other appropriate action in relation to misuse of this service.

Personal Information Collection Statement
Your personal information will be passed to the Contributor and/or its authorised service provider to assist the Contributor to contact you about your investment enquiry. They are required not to use your information for any other purpose. Our privacy policy explains how we store personal information and how you may access, correct or complain about the handling of personal information.


Sign In or Join Free to comment